AbbVie (ABBV.US) announced that FDA approved its IL-23 inhibitor risankizumab (Skyrizi) for the treatment of moderate to severe active ulcerative colitis in adults.
AbbVie (ABBV.US) announced that FDA approved its IL-23 inhibitor risankizumab (Skyrizi) for the treatment of moderate to severe active ulcerative colitis in adults on June 18th. It became the first IL-23 specific inhibitor approved for the treatment of moderate to severe ulcerative colitis and moderate to severe Crohn's disease. Risankizumab has now been approved for four immunomodulatory inflammatory disease indications.
Dr. Roopal Thakkar, MD, Senior Vice President and Chief Medical Officer of AbbVie's global medical department, said, "Today's approval of SKYRIZI for the treatment of ulcerative colitis expands our IBD product portfolio and demonstrates our commitment to helping address patients' ongoing needs."